Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
PTCT - PTC Therapeutics, Inc.
Market Cap 2.98B P/E - EPS this Y 39.40% Ern Qtrly Grth -
Income -479.52M Forward P/E -12.15 EPS next Y 23.10% 50D Avg Chg -5.00%
Sales 900.45M PEG 0.75 EPS past 5Y - 200D Avg Chg -10.00%
Dividend N/A Price/Book N/A EPS next 5Y -9.51% 52W High Chg -33.00%
Recommedations 2.60 Quick Ratio 2.10 Shares Outstanding 76.92M 52W Low Chg 21.00%
Insider Own 2.35% ROA -7.39% Shares Float 60.78M Beta 0.65
Inst Own 105.88% ROE - Shares Shorted/Prior 5.22M/5.95M Price 40.20
Gross Margin 33.06% Profit Margin -53.25% Avg. Volume 844,543 Target Price 38.85
Oper. Margin -17.87% Earnings Date Oct 24 Volume 342,264 Change -1.16%
Healthcare | Biotechnology | United States
About PTC Therapeutics, Inc.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

PTC Therapeutics, Inc. News
08:00 AM PTC Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
12/19/24 PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich Ataxia
12/17/24 PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/10/24 UniQure Stock Doubles After Striking A Deal With The FDA For Huntington's Drug
12/04/24 PTC Therapeutics price target raised to $71 from $47 at UBS
12/03/24 Novartis In-Licenses PTCT's Huntington's Disease Drug for $2.9 Billion
12/03/24 PTCT Stock Soars on Licensing Deal With NVS for Huntington's Therapy
12/03/24 Novartis and PTC Therapeutics link to develop Huntington’s therapy
12/02/24 PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Tops Profit-Taking Zone
12/02/24 Sector Update: Health Care Stocks Slipping Late Afternoon
12/02/24 PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program
12/02/24 PTC Therapeutics Stock Soars on Novartis Licensing Agreement
12/02/24 Novartis' $2.9 Billion Huntington's Bet Sends PTC Stock Soaring Over 14%
12/02/24 PTC Therapeutics Strikes Up to $2.9 Billion Licensing Deal With Novartis for Huntington's Disease Drug Candidate
12/02/24 PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program
12/02/24 Novartis wagers billions of dollars on PTC Huntington’s drug
11/28/24 PTC Therapeutics to sell Priority Review Voucher for $150M
11/27/24 PTC Therapeutics ALS drug fails to meet endpoints as trials shut down
11/27/24 PTC Therapeutics Ends Utreloxastat Development After Rare Neurodegenerative Disease Trial Misses Goal, Analyst Maintains Outperform With Focus On Sepiapterin, Huntington's Programs
11/27/24 PTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 Million
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Gravier Pierre CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER Dec 12 Buy 25.8099 7,700 198,736 33,700 12/14/23
Almstead Neil Gregory CHIEF TECHNICAL OPS.. CHIEF TECHNICAL OPS OFFICER Jan 09 Sell 41.66 759 31,620 3,385 01/11/23
Hill Emily Luisa CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER Jan 09 Sell 41.6562 758 31,575 48,001 01/11/23
Boulding Mark Elliott EXEC. VP AND CLO EXEC. VP AND CLO Jan 09 Sell 41.6562 835 34,783 77,275 01/11/23
Klein Matthew B. CHIEF OPERATING OFFI.. CHIEF OPERATING OFFICER Jan 09 Sell 41.6562 731 30,451 82,373 01/11/23
Pauwels Eric CHIEF BUSINESS OFFIC.. CHIEF BUSINESS OFFICER Jan 09 Sell 41.6562 858 35,741 67,505 01/11/23
Peltz Stuart Walter CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Jan 09 Sell 41.66 2,065 86,028 56,551 01/11/23
Utter Christine Marie SVP, FINANCE & CAO SVP, FINANCE & CAO Jan 09 Sell 41.6562 706 29,409 39,290 01/11/23
Utter Christine Marie SVP, Finance & CAO SVP, Finance & CAO Feb 01 Sell 40.19 1,020 40,994 25,405 02/03/22
Peltz Stuart Walter Chief Executive Offi.. Chief Executive Officer Feb 01 Sell 40 2,243 89,720 38,728 02/03/22
Pauwels Eric Chief Business Offic.. Chief Business Officer Feb 01 Sell 40.002 367 14,681 50,594 02/03/22
Hill Emily Luisa Chief Financial Offi.. Chief Financial Officer Feb 01 Sell 40.002 553 22,121 37,169 02/03/22
Boulding Mark Elliott Exec. VP and CLO Exec. VP and CLO Feb 01 Sell 40.002 779 31,162 61,110 02/03/22
Almstead Neil Gregory Chief Technical Ops.. Chief Technical Ops Officer Feb 01 Sell 40 632 25,280 2,420 02/03/22
Peltz Stuart Walter Chief Executive Offi.. Chief Executive Officer Jan 25 Sell 39.314 330 12,974 39,010 01/27/22
Pauwels Eric Chief Business Offic.. Chief Business Officer Jan 25 Sell 39.314 359 14,114 50,961 01/27/22
Hill Emily Luisa Chief Financial Offi.. Chief Financial Officer Jan 25 Sell 39.314 211 8,295 37,722 01/27/22
Almstead Neil Gregory Chief Technical Ops.. Chief Technical Ops Officer Jan 25 Sell 39.314 43 1,691 2,447 01/27/22
Utter Christine Marie SVP, Finance & CAO SVP, Finance & CAO Jan 07 Sell 38.53 747 28,782 16,253 01/11/22
Almstead Neil Gregory Chief Technical Ops.. Chief Technical Ops Officer Jan 07 Sell 38.53 801 30,863 1,710 01/11/22
Boulding Mark Elliott Exec. VP and CLO Exec. VP and CLO Jan 07 Sell 38.53 885 34,099 47,489 01/11/22
Hill Emily Luisa Chief Financial Offi.. Chief Financial Officer Jan 07 Sell 38.53 800 30,824 22,333 01/11/22
Klein Matthew B. Chief Operating Offi.. Chief Operating Officer Jan 07 Sell 38.53 775 29,861 16,461 01/11/22
Svoronos Dawn Director Director Jan 07 Sell 38.53 510 19,650 26,555 01/11/22
Almstead Neil Gregory Chief Technical Ops.. Chief Technical Ops Officer Jan 27 Sell 62.65 541 33,894 1,847 01/27/21
Klein Matthew B. Chief Development Of.. Chief Development Officer Jan 08 Option 38.98 3,886 151,476 23,195 01/08/21
Klein Matthew B. Chief Development Of.. Chief Development Officer Jan 08 Sell 68.98 3,886 268,056 19,309 01/08/21
Hill Emily Luisa Chief Financial Offi.. Chief Financial Officer Jan 07 Sell 62.37 288 17,963 13,322 01/07/21
Pauwels Eric Chief Business Offic.. Chief Business Officer Jan 07 Sell 62.37 1,067 66,549 27,080 01/07/21
Peltz Stuart Walter Chief Executive Offi.. Chief Executive Officer Jan 07 Sell 62.37 2,068 128,981 11,754 01/07/21
Peltz Stuart Walter Chief Executive Offi.. Chief Executive Officer Dec 31 Option 31.94 285,718 9,125,833 172,022 12/31/20
Peltz Stuart Walter Chief Executive Offi.. Chief Executive Officer Dec 31 Sell 62.32 285,718 17,805,946 56,085 12/31/20
Reeve Emma Director Director Dec 16 Option 33.02 3,000 99,060 2,678 12/16/20
Reeve Emma Director Director Dec 16 Sell 68 1,972 134,096 1,650 12/16/20
Peltz Stuart Walter Chief Executive Offi.. Chief Executive Officer Dec 09 Option 18.76 348,417 6,536,303 193,585 12/09/20
Peltz Stuart Walter Chief Executive Offi.. Chief Executive Officer Dec 09 Sell 62.58 348,417 21,803,936 56,085 12/09/20
Peltz Stuart Walter Chief Executive Offi.. Chief Executive Officer Dec 09 Option 14.9 20,017 298,253 63,293 12/09/20
Peltz Stuart Walter Chief Executive Offi.. Chief Executive Officer Dec 09 Sell 62.2 20,017 1,245,057 56,085 12/09/20
Peltz Stuart Walter Chief Executive Offi.. Chief Executive Officer Nov 06 Option 21.43 38,328 821,369 20,599 11/06/20
Peltz Stuart Walter Chief Executive Offi.. Chief Executive Officer Nov 03 Option 10.85 50,000 542,500 106,085 11/03/20
Peltz Stuart Walter Chief Executive Offi.. Chief Executive Officer Nov 03 Sell 53.93 50,000 2,696,500 56,085 11/03/20
Peltz Stuart Walter Chief Executive Offi.. Chief Executive Officer Oct 07 Option 10.93 179,811 1,965,334 107,910 10/07/20
Peltz Stuart Walter Chief Executive Offi.. Chief Executive Officer Oct 07 Sell 50.08 179,811 9,004,935 56,085 10/07/20
Utter Christine Marie SVP, Finance & CAO SVP, Finance & CAO Oct 07 Option 14.62 3,287 48,056 12,062 10/07/20
Utter Christine Marie SVP, Finance & CAO SVP, Finance & CAO Oct 07 Sell 49.38 3,287 162,312 9,562 10/07/20